Save Product
Product Details
Materials Provided
IDComponentsSizeEP117-C01High-bind Plate1 plateEP117-C02Human CTLA-410 μgEP117-C03Biotinylated Human B7-265 μgEP117-C04Anti-CTLA-4 Neutralizing Antibody20 μgEP117-C05Streptavidin-HRP10 μgEP117-C06Coating Buffer12 mLEP117-C0710xWashing Buffer50 mLEP117-C08Blocking Buffer50 mLEP117-C09Substrate Solution24 mLEP117-C10Stop Solution7 mLProduct Overview
B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human B7-2 binding to human CTLA-4. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human B7-2 binding to human CTLA-4.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF B7-2 [BIOTINYLATED]: CTLA-4 BINDING BY ANTI-CTLA-4 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-CTLA-4 Neutralizing antibody (Catalog # EP117-C04) (1:1 serial dilution, from 10 μg/mL to 0.01μg/mL) was added into CTLA-4: Biotinylated B7-2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Cytotoxic T-Lymphocyte-Associated Antigen 4
- Category：
- Approved Drugs：
5 Details
- Drugs in Clinical Trials：
65 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
